Hepatocellular carcinoma beyond Milan criteria: Management and transplant selection criteria

Table 2 Expanded criteria that incorporate tumor biomarkers for hepatocellular carcinoma-liver transplantation

Ref.	Year	Morphometric criteria	Biomarker criteria	Donor type	n	Survival
Kwon et al[34]	2007	Any number of lesions ≤ 5 cm each	AFP ≤ 400 ng/mL	Living	139	5 yr OS: 79.9%
Takada et al[38]	2007	Up to 10 lesions ≤ 5 cm each	PIVKA-II ≤ 400 mAU/mL	Living	136	5 yr OS: 87%
Zheng et al[29]	2008	Total tumor diameter ≤ 8 cm or total	If total	Cadaveric	195	5 yr OS: 70.7%, 5 yr DFS: 62.4%
		tumor diameter > 8 cm with histopathologic grade I or II	tumor diameter > 8 cm: AFP ≤ 400 ng/mL
Fujiki et al[37]	2009	Up to 10 lesions ≤ 5 cm each	DCP ≤ 400 mAU/mL	Living	144	5 yr OS: 89%
Lai et al[31]	2012	Total tumor diameter ≤ 8 cm	AFP ≤ 400 ng/mL	Cadaveric	158	5 yr DFS: 74.4%
Grąt et al[36]	2014	UCSF or Up-to-7 criteria	AFP < 100 ng/mL	Cadaveric	121	5 yr OS: 100%
Toso et al[35]	2015	Total tumor volume ≤ 115 cm3	AFP ≤ 400 ng/mL	Cadaveric	166	4 yr OS: 74.6%
Lee et al[39]	2015	Total tumor diameter ≤ 10 cm	PET/CT negative uptake	Living	280	5 yr OS: 73.4%,
						5 yr DFS: 80.4%

AFP: Alpha fetal protein; UCSF: University of California, San Francisco; DFS: Disease free survival; PIVKA-II: Protein induced by vitamin K absence or antagonism factor II; OS: Overall survival.